Want to see HK:1863 full AI Analyst Report?
China Longevity Group Co. Ltd. (1863) AI Stock Analysis
China Longevity Group Co. Ltd.
(HKEX:1863)
The overall score is driven mainly by mixed financial performance: the business maintains sizable revenue, positive equity and manageable leverage, but growth has cooled, margins have compressed, and free cash flow conversion is extremely weak, creating significant cash flow risk; valuation, with a mid‑20s P/E and no dividend, is only moderately appealing and does not fully offset the underlying weakness in cash generation.
China Longevity Group Co. Ltd. Business Overview & Revenue Model
Company Description
China Longevity Group operates within the reinforced materials industry, engaging comprehensively in the design, development, production, and distribution of its specialized products. These offerings include advanced polymer-processed polyester fabri...
China Longevity Group Co. Ltd. Financial Statement Overview
Summary
Revenue remains sizable at RMB1.17 billion and the company is still profitable, but a 3.2% top-line decline, margin compression across gross, operating and net levels, and extremely weak free cash flow relative to net income point to pressured earnings quality and cash generation despite a manageable, moderately leveraged balance sheet.
Income Statement
52NeutralBalance Sheet
58NeutralCash Flow
33Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.18B | 1.17B | 1.17B | 933.93M | 926.62M | 1.44B |
| Gross Profit | 205.48M | 203.90M | 202.74M | 186.04M | 146.32M | 260.47M |
| EBITDA | 117.55M | 106.46M | 127.29M | 127.75M | 118.23M | 191.28M |
| Net Income | 43.54M | 43.19M | 55.55M | 63.00M | 46.19M | 106.93M |
Balance Sheet | ||||||
| Total Assets | 1.98B | 1.98B | 1.94B | 1.71B | 1.33B | 1.39B |
| Cash, Cash Equivalents and Short-Term Investments | 178.41M | 178.41M | 83.35M | 64.36M | 90.58M | 77.99M |
| Total Debt | 724.45M | 724.45M | 680.75M | 619.57M | 332.50M | 255.45M |
| Total Liabilities | 1.11B | 1.11B | 1.11B | 951.79M | 688.27M | 831.66M |
| Stockholders Equity | 797.67M | 797.67M | 749.28M | 676.42M | 599.34M | 531.17M |
Cash Flow | ||||||
| Free Cash Flow | 1.93M | 1.85M | -23.86M | -354.53M | -138.53M | 55.80M |
| Operating Cash Flow | 110.62M | 108.71M | 103.56M | -10.62M | 35.14M | 177.51M |
| Investing Cash Flow | -106.50M | -104.77M | -135.18M | -333.16M | -95.10M | -201.75M |
| Financing Cash Flow | 42.82M | 42.15M | 50.22M | 317.36M | 73.07M | 67.21M |
China Longevity Group Co. Ltd. Peers Comparison
Overall Rating
HK:183068Neutral
HK:386954Neutral- HK:186350Neutral
HK:072242Neutral
HK:213842Neutral
HK:388641Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1830 | 68Neutral | HKD 1.43B | 8.01 | 43.78% | 12.76% | -14.68% | -13.60% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:3869 | 54Neutral | HKD 467.79M | -143.32 | -0.41% | ― | 3.16% | -101.02% |
| HK:1863 | 50Neutral | ― | 22.70 | 5.57% | ― | 6.49% | -5.55% |
| HK:0722 | 42Neutral | HKD 292.35M | -3.79 | -10.76% | 9.04% | -1.37% | -334.69% |
| HK:2138 | 42Neutral | HKD 645.94M | -1.61 | -25.36% | ― | -8.94% | -140.82% |
| HK:3886 | 41Neutral | HKD 1.10B | 78.09 | 0.48% | 1.10% | -3.26% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1830 | Perfect Medical Health Management Limited | 1.14 | -0.08 | -6.79% | |
| HK:2138 | EC Healthcare | 0.55 | -0.10 | -16.15% | |
| HK:3869 | Hospital Corporation of China Ltd | 3.38 | -2.61 | -43.49% | |
| HK:3886 | Town Health International Medical Group Ltd. | 0.16 | -0.11 | -40.07% | |
| HK:0722 | UMP Healthcare Holdings Limited | 0.36 | -0.07 | -16.67% |
China Longevity Group Co. Ltd. Corporate Events
China Longevity Group Lifts Interim Profit Despite Margin Pressure
China Longevity Group reported interim revenue of about RMB646.1 million for the six months ended 30 June 2026, a year-on-year increase of 9.2%, though its gross profit margin slipped from 17.0% to 15.6%, reflecting pressure on margins despite higher...
China Longevity Group Sets Board Meeting to Review Interim Results and Dividend
China Longevity Group Company Limited has scheduled a board meeting for 31 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider the potential declaration and payment of an interim d...
China Longevity Group Still Healthy but Faces Prolonged Trading Suspension Review
China Longevity Group Company Limited, a Cayman Islands-incorporated issuer listed in Hong Kong under stock code 1863, operates a group structure engaged in production and materials-related activities. The company highlights research and development...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026